<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03237000</url>
  </required_header>
  <id_info>
    <org_study_id>7</org_study_id>
    <nct_id>NCT03237000</nct_id>
  </id_info>
  <brief_title>Effect of Administering Intravenous Magnesium Sulfate on Fetal Cardiotocography and Neonatal Outcome in Preeclamptic Patients</brief_title>
  <official_title>Effect of Administering Intravenous Magnesium Sulfate Heptahydrate (MgSO4â€¢7H2O) on Fetal Cardiotocography and Neonatal Outcome in Preeclamptic Patients in 3rd Trimester of Pregnancy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Admission CTG for 20 minutes Settings on a CTG machine was standardised to enable a&#xD;
      consistent approach of interpretation of traces. Paper speed of 3cm per minute will be&#xD;
      adopted. Maternal heart rate was recorded and noted on CTG. Following birth date, time and&#xD;
      mode of delivery will be labelled on CTG.&#xD;
&#xD;
      Magnesium sulphate was administered by continuous intravenous infusion according to our&#xD;
      hospital protocol as follows:&#xD;
&#xD;
        -  Loading dose: 4-6 gm of magnesium sulphate diluted in 100 mL of IV fluid administered&#xD;
           over 15-20 min.&#xD;
&#xD;
        -  Maintenance dose: 2 gm/hr in 100 mL of IV infusion to be continued for 24 hours after&#xD;
           delivery.&#xD;
&#xD;
      Another 20 minutes CTG strip will be performed 20 minutes after administration of IV loading&#xD;
      MgSO4, 7H2O and thus ensuring that MgSO4 has reached peak serum levels&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Admission CTG:&#xD;
&#xD;
      Admission CTG will be performed for 20 minutes&#xD;
&#xD;
      I-Settings:&#xD;
&#xD;
        1. Settings on a CTG machine will be standardised to enable a consistent approach of&#xD;
           interpretation of traces.&#xD;
&#xD;
        2. Paper speed of 3cm per minute will be adopted.&#xD;
&#xD;
        3. CTGs will be labelled with mother's name, hospital number.&#xD;
&#xD;
        4. Date and time settings on machines will be labelled at commencement of tracing.&#xD;
&#xD;
        5. Maternal heart rate will be recorded and noted on CTG.&#xD;
&#xD;
        6. Following birth date, time and mode of delivery will be labelled on CTG.&#xD;
&#xD;
      Magnesium Sulphate hepatahydrate administration:&#xD;
&#xD;
      Magnesium sulphate will be administered by continuous intravenous infusion according to our&#xD;
      hospital protocol as follows:&#xD;
&#xD;
        -  Loading dose: 4-6 gm of magnesium sulphate diluted in 100 mL of IV fluid administered&#xD;
           over 15-20 min.&#xD;
&#xD;
        -  Maintenance dose: 2 gm/hr in 100 mL of IV infusion to be continued for 24 hours after&#xD;
           delivery.&#xD;
&#xD;
        -  Magnesium toxicity was monitored by hourly assessment of:&#xD;
&#xD;
             1. Patellar reflexes should be present.&#xD;
&#xD;
             2. Respiratory rate not &lt; 16/min.&#xD;
&#xD;
             3. Urine output not &lt; 100ml / hr. Another 20 minutes CTG strip will be performed 20&#xD;
                minutes after administration of IV loading MgSO4, 7H2O and thus ensuring that MgSO4&#xD;
                has reached peak serum levels&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">August 1, 2017</start_date>
  <completion_date type="Anticipated">January 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Magnesium sulphate was administered by continuous intravenous infusion according to our hospital protocol as follows:&#xD;
Loading dose: 4-6 gm of magnesium sulphate diluted in 100 mL of IV fluid administered over 15-20 min.&#xD;
Maintenance dose: 2 gm/hr in 100 mL of IV infusion to be continued for 24 hours after delivery.</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fetal heart rate tracing</measure>
    <time_frame>20 minutes after MgSO4 administration</time_frame>
    <description>Settings on a CTG machine is standardised to enable a consistent approach of interpretation of traces. Paper speed of 3cm per minute is adopted</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Preeclampsia</condition>
  <arm_group>
    <arm_group_label>MgSO4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Magnesium sulphate was administered by continuous intravenous infusion according to our hospital protocol as follows:&#xD;
Loading dose: 4-6 gm of magnesium sulphate diluted in 100 mL of IV fluid administered over 15-20 min.&#xD;
Maintenance dose: 2 gm/hr in 100 mL of IV infusion to be continued for 24 hours after delivery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MgSO4</intervention_name>
    <description>Magnesium sulphate was administered by continuous intravenous infusion according to our hospital protocol as follows:&#xD;
Loading dose: 4-6 gm of magnesium sulphate diluted in 100 mL of IV fluid administered over 15-20 min.&#xD;
Maintenance dose: 2 gm/hr in 100 mL of IV infusion to be continued for 24 hours after delivery.</description>
    <arm_group_label>MgSO4</arm_group_label>
    <other_name>Magnisium sulfate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Pregnant Women in the third trimester.&#xD;
&#xD;
          2. Severely preeclamptic patients.&#xD;
&#xD;
          3. Singleton Pregnancy.&#xD;
&#xD;
          4. Patients with normal admission CTG&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Evidence of fetal anomalies on scan.&#xD;
&#xD;
          2. Concomitant maternal morbidities as diabetes, cardiac disease.&#xD;
&#xD;
          3. Patients contraindicated to take MgSo4 e.g.: advanced renal disease.&#xD;
&#xD;
          4. Abnormal admission CTG.&#xD;
&#xD;
          5. Morbid obesity.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmed Maged, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>kasr Alainy medical school</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ahmed Maged, MD</last_name>
    <phone>01005227404</phone>
    <email>prof.ahmedmaged@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ahmed Ibrahim, MD</last_name>
    <email>gyndoctor77@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kasr Alainy medical school</name>
      <address>
        <city>Cairo</city>
        <zip>12151</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>July 31, 2017</study_first_submitted>
  <study_first_submitted_qc>July 31, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 2, 2017</study_first_posted>
  <last_update_submitted>July 31, 2017</last_update_submitted>
  <last_update_submitted_qc>July 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Ahmed Maged</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Preeclampsia</keyword>
  <keyword>MgSO4</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pre-Eclampsia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

